Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the target of a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 685,800 shares, a decline of 23.7% from the August 15th total of 899,200 shares. Based on an average daily volume of 503,100 shares, the days-to-cover ratio is currently 1.4 days. Currently, 3.6% of the shares of the stock are sold short.

Vigil Neuroscience Price Performance

VIGL traded down $0.01 during trading on Friday, hitting $3.67. 43,274 shares of the stock traded hands, compared to its average volume of 96,475. The firm has a market capitalization of $145.52 million, a P/E ratio of -1.73 and a beta of 1.96. The firm has a 50-day moving average of $3.75 and a 200 day moving average of $3.52. Vigil Neuroscience has a 12-month low of $2.47 and a 12-month high of $9.24.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.02. As a group, equities analysts predict that Vigil Neuroscience will post -2.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in VIGL. Acadian Asset Management LLC bought a new position in Vigil Neuroscience in the 2nd quarter worth $26,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Vigil Neuroscience in the 2nd quarter worth $87,000. Renaissance Technologies LLC increased its stake in shares of Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company's stock worth $286,000 after acquiring an additional 11,536 shares in the last quarter. Ensign Peak Advisors Inc increased its stake in shares of Vigil Neuroscience by 72.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company's stock worth $1,580,000 after acquiring an additional 166,442 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Vigil Neuroscience by 11.9% in the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company's stock worth $3,050,000 after acquiring an additional 95,276 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $17.00 target price on shares of Vigil Neuroscience in a research report on Wednesday, August 14th. Wedbush restated an "outperform" rating and issued a $23.00 price objective on shares of Vigil Neuroscience in a report on Thursday, July 11th. Finally, Guggenheim lowered their price objective on shares of Vigil Neuroscience from $17.00 to $16.00 and set a "buy" rating for the company in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Vigil Neuroscience has an average rating of "Moderate Buy" and a consensus target price of $16.60.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.